Get started
Author

Tao Zhu

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
2021 · Shipo Wu, Jianying Huang, et al. · The Lancet Infectious Diseases · 289
PDF
Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
2021 · Scott A Halperin, Lingyun Ye, et al. · The Lancet · 226
PDF
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
2015 · Feng-Cai Zhu, Li-Hua Hou, et al. · The Lancet · 193
PDF
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial
2022 · Jing-Xin Li, Shi-Po Wu, et al. · The Lancet Respiratory Medicine · 169
PDF
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
2022 · Jingxin Li, Lihua Hou, et al. · Nature Medicine · 153
PDF
The nano delivery systems and applications of mRNA
2021 · Mingyuan Li, Yuan Li, et al. · European Journal of Medicinal Chemistry · 127
PDF
Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients
2021 · Yuanling Yu, Meiyu Wang, et al. · Signal Transduction and Targeted Therapy · 123
PDF
Safety and Immunogenicity of a Recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial
2021 · Fengcai Zhu, Pengfei Jin, et al. · Clinical Infectious Diseases · 109
Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine
2023 · Mingyuan Li, Lin Jia, et al. · npj Vaccines · 88
PDF
Safety and Immunogenicity of Aerosolised Ad5-nCoV or Intramuscular Ad5-nCoV or Inactivated COVID-19 Vaccine Coronavac Given as the Second Booster Following Three Doses of CoronaVac: A Multicentre, Open-Label, Phase 4, Randomized Trial
2022 · Rong Tang, Hui Zheng, et al. · The Lancet Respiratory Medicine · 64
PDF
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial
2023 · Jing-Xin Li, Li-Hua Hou, et al. · The Lancet Infectious Diseases · 61
PDF
AdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human Primates
2015 · Mangalakumari Jeyanathan, Zhongqi Shao, et al. · PLoS ONE · 60
PDF
Synthesis, α-glucosidase inhibitory and molecular docking studies of prenylated and geranylated flavones, isoflavones and chalcones
2015 · Hua Sun, Yashan Li, et al. · Bioorganic & Medicinal Chemistry Letters · 58
Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques
2022 · Fang Xu, Shipo Wu, et al. · Emerging Microbes & Infections · 50
An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates
2016 · Shipo Wu, Andrea Kroeker, et al. · The Journal of Infectious Diseases · 38
PDF
N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma
2021 · Tingshen Li, Peng Yu, et al. · European Journal of Medicinal Chemistry · 37
Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate
2016 · Chun Fang Shen, Danielle Jacob, et al. · Vaccine · 33
Heterologous prime-boost immunization with CoronaVac and Convidecia
2021 · Jingxin Li, Lihua Hou, et al. · medRxiv · 31
PDF
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
2022 · Lairun Jin, Rong Tang, et al. · Emerging Microbes & Infections · 30
Liver macrophages and sinusoidal endothelial cells execute vaccine-elicited capture of invasive bacteria
2023 · Juanjuan Wang, Haoran An, et al. · Science Translational Medicine · 29
PDF
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial
2023 · Jun-Dong Wu, Jing-Xin Li, et al. · The Lancet Infectious Diseases · 28
PDF
Total synthesis of (±)-Anastatins A and B
2015 · Guojun Pan, Yantao Ma, et al. · Tetrahedron Letters · 18
Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients
2023 · Zhe Zhang, Shipo Wu, et al. · Frontiers in Immunology · 16
Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming
2022 · Zhe Zhang, Shipo Wu, et al. · medRxiv · 16
PDF
Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector–Based Ebola Vaccine (Ad5-EBOV) Virus Titer
2018 · Yuhua Li, Ling Wang, et al. · Human Gene Therapy Clinical Development · 16
Works count: 69
Citation count: 2,266
H-index: 21
I10-index: 35
Year
Topic
Type